Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Warfarin · Athrombin-K, Coumadin

Small molecule · Inhibitor of vitamin K epoxide reductase · developed by Bristol Myers Squibb

Approved FDA, Jun 1954
1 Registered trials

What is Warfarin?

Warfarin is a synthetic anticoagulant that inhibits the regeneration of vitamin K1 epoxide, reducing synthesis of vitamin K-dependent clotting factors II, VII, IX and X and the anticoagulant proteins C and S. It is studied in nonalcoholic steatohepatitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Athrombin-K, Coumadin, Panwarfin
Drug type
Small molecule
Targets
vitamin K epoxide reductase
Mechanism
Inhibitor of vitamin K epoxide reductase
Pathways
vitamin K cycle, vitamin K-dependent clotting factor synthesis, gamma-carboxylation of clotting factors
Therapy area
Gastroenterology
Developer
Bristol Myers Squibb
In trials of
ALT
FDA status
Approved as Athrombin-K, Coumadin, Panwarfin (June 8, 1954), NDA009218
UNII
09CC5J5C8A

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04972396 Phase 1 NASH - Nonalcoholic Steatohepatitis Completed ALT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

NASH - Nonalcoholic Steatohepatitis

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.